Key result
Self-expanding apical closure device achieves 100% deployment success without adverse events in a porcine model.
Why the study?
Closed-chest transapical valve implantations and cardiac structural procedures requiring large-sized introducer sheaths cannot be safely performed with available technology.
Does a self-expanding apical closure device safely seal percutaneous access sites made with large-sized introducer sheaths in a closed-chest animal model?
Does a self-expanding apical closure device safely seal percutaneous access sites made with large-sized introducer sheaths in a closed-chest animal model?
A self-expanding apical closure device successfully and safely sealed percutaneous access sites made with large-sized introducer sheaths in a preclinical pig model, suggesting feasibility for full-percutaneous transapical structural procedures.
Answers are grounded in this paper and cite their sources.
Device feasible in porcine model without complications; leaves open translation to human transapical procedures.
BACKGROUND: Closed-chest transapical valve implantations (aortic, mitral, and tricuspid) and cardiac structural procedures requiring large-sized introducer sheaths cannot be safely performed with the available technology. We tested a self-expanding apical closure device in a closed-chest animal model, using large-sized introducer sheaths and human-sized animals to establish the technique for future tests in humans. METHODS: Six human-sized pigs (mean weight: 89.7 ± 3.7 kg) received general anesthesia, intubation, and full heparinization (15,000 IU/animal; expected activated clotting time >200 s). Under fluoroscopy and multimodality imaging guidance with next-generation fusion imaging prototypes, a 15-cm long needle and a standard guidewire were percutaneously inserted under the xiphoidal aponeurosis and into the ventricular apex. After the exchange with a stiff guidewire, a 21-Fr introducer sheath for transapical procedures (outer diameter: 25-Fr) was placed in the left ventricle through the apex. The self-expanding closure device was inserted and deployed under fluoroscopic guidance while the 21-Fr sheath was gently removed. Hemodynamic conditions were monitored for 30 min and then the chest was opened to inspect the closure device and quantify the blood loss in the pericardium. Animals were killed and the hearts were removed and inspected. RESULTS: All six apical closure devices were successfully deployed without adverse events. No death, hemodynamic collapse, or cardiac tamponade occurred during the 30-min observational period (mean systolic and diastolic pressures: 88 ± 11 and 58 ± 13 mmHg, respectively; mean heart rate: 60 ± 11 beats per minutes). Pre- and postdeployment (after protamine administration) mean activated clotting time was 541 ± 263 and 217 ± 62 s, respectively. The plugs provided good sealing with a mean of 27.2 ± 13.86 ml of blood lost in the pericardium. Postmortem inspection showed good plug fixation without myocardial damage. CONCLUSION: This self-expanding apical closure device successfully sealed the percutaneous access sites made with large-sized introducer sheaths in human-sized animals. This preclinical study suggests that transapical valve and structural procedures requiring large-sized introducer sheaths can be performed percutaneously.
No takes yet. Share an insight, caveat, or question.
Ferrari et al. (2022) studied Transapical structural and valve procedures (n=6). Self-expanding apical closure device was evaluated on Successful deployment without adverse events (death, hemodynamic collapse, or cardiac tamponade). A self-expanding apical closure device was successfully deployed in 6 human-sized pigs without adverse events, providing good sealing with a mean pericardial blood loss of 27.2 ml.
Synapse has enriched 10 related papers. Consider them for comparative context: